健脾理气方配合肝动脉化疗灌注栓塞治疗原发性肝癌的临床疗效及安全性分析
[摘要] 目的 分析健脾理氣方配合肝动脉化疗灌注栓塞治疗原发性肝癌的临床疗效及安全性。 方法 选取2015年2月～2019年2月在我院接受治疗的原发性肝癌患者86例，采用随机数字表法分为两组，各43例。两组均行肝动脉化疗栓塞治疗，对照组在肝动脉化疗栓塞治疗后给予常规西医治疗，观察组则加用健脾理气方治疗。对比两组临床疗效、治疗前后肝功能水平变化及不良反应。 结果 观察组治疗有效率为60.47%，高于对照组37.21%，差异有统计学意义(P<0.05);观察组治疗后ALT水平为(66.42±18.25)U/L、AST水平为(73.66±10.28)U/L、TBIL水平为(30.63±11.29)mmol/L，均低于对照组的(90.17±16.34)U/L、(120.41±20.69)U/L、(36.28±13.71)mmol/L，差异有统计学意义(P<0.05);观察组骨髓抑制、感染、恶心呕吐、肝功能损伤发生率分别为25.58%、6.98%、16.28%、27.91%，均低于对照组的46.51%、23.26%、34.88%及48.84%，差异有统计学意义(P<0.05)。 结论 健脾理气方配合肝动脉灌注化疗栓塞介入治疗原发性肝癌可获得较好的临床疗效，有利于改善肝功能指标，缓解化疗产生的不良反应，值得推广应用。
[关键词] 原发性肝癌;健脾理气方;肝动脉栓塞介入治疗;盐酸表柔比星;肝功能;不良反应
[中图分类号] R735.7 [文献标识码] B [文章编号] 1673-9701(2020)01-0076-03
Clinical efficacy and safety analysis of Jianpi Liqi decoction combined with hepatic arterial chemoembolization in the treatment of primary liver cancer
CHEN Yan PAN Yunling CHEN Jian
Department of Integrated Traditional Chinese and Western Medicine Oncology， Fuzhou First Hospital， Fuzhou 350004， China
[Abstract] Objective To analyze the clinical efficacy and safety of Jianpi Liqi decoction combined with hepatic arterial chemoembolization in the treatment of primary liver cancer. Methods 86 patients with primary liver cancer who underwent treatment from February 2015 to February 2019 in our hospital were enrolled. The patients were randomly divided into two groups， with 43 cases in each group. Hepatic arterial chemoembolization was performed in both groups. The control group was treated with conventional Western medicine after hepatic arterial chemoembolization， and the observation group was treated with Jianpi Liqi decoction. The clinical efficacy， changes in liver function levels before and after treatment and adverse reactions between the two groups were compared. Results The effective rate was 60.47% in the observation group， which was higher than that in the control group (37.21%)， and the difference was statistically significant(P<0.05). The ALT (66.42±18.25) U/L， AST (73.66±10.28) U/L and TBIL (30.63±11.29) mmol/L in the observation group were lower than those of the control group (90.17±16.34) U/L， (120.41±20.69) U/L， (36.28±13.71) mmol/L，and the difference was statistically significant(P<0.05). The incidence of myelosuppression， infection， nausea and vomiting and liver function injury in the observation group were 25.58%， 6.98%， 16.28%， and 27.91%， respectively， which were lower than those of the control group (46.51%， 23.26%， 34.88% and 48.84%)， and the difference was statistically significant(P<0.05). Conclusion Jianpi Liqi decoction combined with hepatic arterial chemoembolization for the treatment of primary liver cancer can obtain better clinical efficacy， improve liver function indicators， and alleviate the adverse reactions caused by chemotherapy. It is worthy of popularization and application., 百拇医药(陈艳 潘云苓 陈坚)
[关键词] 原发性肝癌;健脾理气方;肝动脉栓塞介入治疗;盐酸表柔比星;肝功能;不良反应
[中图分类号] R735.7 [文献标识码] B [文章编号] 1673-9701(2020)01-0076-03
Clinical efficacy and safety analysis of Jianpi Liqi decoction combined with hepatic arterial chemoembolization in the treatment of primary liver cancer
CHEN Yan PAN Yunling CHEN Jian
Department of Integrated Traditional Chinese and Western Medicine Oncology， Fuzhou First Hospital， Fuzhou 350004， China
[Abstract] Objective To analyze the clinical efficacy and safety of Jianpi Liqi decoction combined with hepatic arterial chemoembolization in the treatment of primary liver cancer. Methods 86 patients with primary liver cancer who underwent treatment from February 2015 to February 2019 in our hospital were enrolled. The patients were randomly divided into two groups， with 43 cases in each group. Hepatic arterial chemoembolization was performed in both groups. The control group was treated with conventional Western medicine after hepatic arterial chemoembolization， and the observation group was treated with Jianpi Liqi decoction. The clinical efficacy， changes in liver function levels before and after treatment and adverse reactions between the two groups were compared. Results The effective rate was 60.47% in the observation group， which was higher than that in the control group (37.21%)， and the difference was statistically significant(P<0.05). The ALT (66.42±18.25) U/L， AST (73.66±10.28) U/L and TBIL (30.63±11.29) mmol/L in the observation group were lower than those of the control group (90.17±16.34) U/L， (120.41±20.69) U/L， (36.28±13.71) mmol/L，and the difference was statistically significant(P<0.05). The incidence of myelosuppression， infection， nausea and vomiting and liver function injury in the observation group were 25.58%， 6.98%， 16.28%， and 27.91%， respectively， which were lower than those of the control group (46.51%， 23.26%， 34.88% and 48.84%)， and the difference was statistically significant(P<0.05). Conclusion Jianpi Liqi decoction combined with hepatic arterial chemoembolization for the treatment of primary liver cancer can obtain better clinical efficacy， improve liver function indicators， and alleviate the adverse reactions caused by chemotherapy. It is worthy of popularization and application., 百拇医药(陈艳 潘云苓 陈坚)